Compare iShares China Large-Cap ETF (FXI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Johnson & Johnson — how do they compare? iShares China Large-Cap ETF trades at $34.6, while Johnson & Johnson trades at $250.9 (market cap $594.63B). The key difference: Johnson & Johnson pays a 2.17% dividend while iShares China Large-Cap ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | JNJ | |
|---|---|---|
52-Week High | $41.75 | $267.24 |
52-Week Low | $31.59 | $162.98 |
Market Cap | — | $594.63B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $627.57B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI is currently trading at $34.545, up 2.29% with strong technical momentum indicated by bullish moving averages and ADX signals. The ETF benefits from China's accelerating AI and manufacturing sectors, with recent news highlighting a $295 billion AI infrastructure plan and robust export growth. However, RSI readings above 89 suggest the ETF is significantly overbought near-term.
The outlook remains positive given China's strategic investments in technology and manufacturing, though investors face risks from US-China trade tensions and potential profit-taking after recent gains. Wall Street sentiment is cautiously optimistic as institutional flows respond to China's economic initiatives.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
